This invention relates to vaccines and in particular to the combination of non- integrating, replication-incompetent retroviral vectors (NIV) with virus-like particle (VLP) vaccines to induce an immune response in an animal host following administration to the host. This combination results in a novel vaccine strategy for delivering priming and boost doses, wherein an effective amount of an NIV is administered to the host, followed by an effective amount of a VLP. The concept can be broadly applied to infectious disease vaccines and also to cancer vaccines.
This invention relates to non-integrating, non-replicating retroviral vectors that cause an immune response in an animal host when administered to the host. The vectors transduce cells in the host, where they produce virus-like particles (VLPs), which stimulate an additional immune response in the host when they are released from the cells. The vectors are non-integrating, non-replicating retroviral vectors comprising long terminal repeats, a packaging sequence, and a heterologous promoter operably linked to one or more polynucleotide sequences that together encode the structural proteins of a virus. Methods of making and using the vectors are also disclosed.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/00 - Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
The invention relates to cell therapy for the treatment of HIV infection in humans. It provides a composition of genetically modified human cells for introduction into the body of a person infected with HIV, to reduce the person's viral load and to provide and reconstitute T-cells that are resistant to HIV infection. The composition comprises allogeneic or autologous human CD4+ T-cells, allogeneic or autologous human hematopoietic stem cells (HSCs), and allogeneic or autologous human mesenchymal stem cells (MSCs). Each cell comprises at least one heterologous anti-HIV sequence that inhibits HIV from infecting the cells or from replicating in the cells and at least one heterologous fate-controlling sequence. The invention also provides lentiviral vectors for making the cells, plasmids and producer cells for making the vectors, and methods for making the genetically modified cells.
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
This invention relates to making proteins in cultures of mammalian cells through the use of lentiviral vectors encoding the protein or proteins of interest. The invention provides a method for making a mammalian cell that produces a protein by transducing a mammalian cell with lentiviral transduction vectors at least 2 times in 24 hours, wherein each lentiviral transduction vector comprises an expressible polynucleotide coding for the protein. In one embodiment, the transduced cell is an apoptosis-resistant cell. The invention further provides mammalian cells and cell lines produced by this method as well as cultures of such cells. The invention also provides a method for making a protein by culturing these cells and cell cultures under conditions effective to produce the protein. The invention further provides an assay for measuring the concentration of a protein in a sample having a high concentration of the protein.
The invention provides vectors which allow efficient expression of genes or RNAs of interest (GROI) which possess internal splicing sites, including the construction of lentiviral vectors where expression of such GROIs do not result a truncated genomic lentiviral vector RNA. Moreover, the lentiviral vector constructs are designed such that expression from the vector can be modulated via inducible promoters. These lentiviral vectors, and in particular HIV vectors, are useful in functional genomics, drug discovery, target validation, protein production, vaccine production, clinical gene therapy, and other applications.
This invention relates to computer and display methods and systems for storing, manipulating, analyzing, linking, retrieving and displaying vector data. The methods and systems are illustrated with reference to data on virus structure, particularly lentiviral structure. In this regard, the invention especially relates to interactive systems for constructing a virus vector and interactive systems for ordering the virus vector from a web site.
C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
C12N 15/75 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
C12N 15/76 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Streptomyces
C12N 15/77 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Brevibacterium
The present invention relates to lentiviral vectors for gene therapy, cancer treatment, producing recombinant proteins, such as antibodies and vaccines, and other therapeutic purposes. Novel lentiviral vectors are disclosed, e.g., comprising helper sequences in opposite orientations and/or minimally functional LTR sequences, which can be used to prepare high efficiency transduction vectors. Vectors are also designed to express silencing RNA and antisense polynucleotides.
A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermen
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
patents